Latest Insider Transactions at Immunome Inc. (IMNM)
This section provides a real-time view of insider transactions for Immunome Inc. (IMNM). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Immunome Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Immunome Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 22
2024
|
Clay B Siegall President and CEO |
BUY
Open market or private purchase
|
Direct |
33,943
+6.13%
|
$305,487
$9.78 P/Share
|
|
Nov 21
2024
|
Clay B Siegall President and CEO |
BUY
Open market or private purchase
|
Direct |
66,057
+11.97%
|
$594,513
$9.54 P/Share
|
|
Nov 21
2024
|
Robert Lechleider Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
15,805
+50.0%
|
$142,245
$9.48 P/Share
|
|
Nov 21
2024
|
Philip Tsai Chief Technology Officer |
BUY
Open market or private purchase
|
Direct |
21,000
+50.0%
|
$189,000
$9.43 P/Share
|
|
Sep 19
2024
|
Max Rosett Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
14,380
-23.25%
|
$230,080
$16.01 P/Share
|
|
Sep 19
2024
|
Max Rosett Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
42,000
+40.44%
|
$42,000
$1.05 P/Share
|
|
Aug 19
2024
|
Jack Higgins Chief Scientific Officer |
SELL
Bona fide gift
|
Direct |
2,471
-15.44%
|
-
|
|
Aug 16
2024
|
Jean Jacques Bienaime |
BUY
Open market or private purchase
|
Direct |
7,000
+29.64%
|
$91,000
$13.94 P/Share
|
|
Aug 15
2024
|
Jack Higgins Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,524
-18.05%
|
$45,812
$13.93 P/Share
|
|
Aug 15
2024
|
Jack Higgins Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
19,524
+50.0%
|
$19,524
$1.35 P/Share
|
|
May 21
2024
|
Jean Jacques Bienaime |
BUY
Open market or private purchase
|
Direct |
2,000
+17.22%
|
$26,000
$13.57 P/Share
|
|
May 21
2024
|
Clay B Siegall President and CEO |
BUY
Open market or private purchase
|
Direct |
20,434
+4.64%
|
$265,642
$13.78 P/Share
|
|
May 20
2024
|
Clay B Siegall President and CEO |
BUY
Open market or private purchase
|
Direct |
79,566
+16.62%
|
$1,034,358
$13.91 P/Share
|
|
Oct 02
2023
|
Clay B Siegall President and CEO |
BUY
Open market or private purchase
|
Direct |
169,204
+34.61%
|
$846,020
$5.91 P/Share
|
|
Oct 02
2023
|
Bruce Turner Chief Strategy Officer |
BUY
Open market or private purchase
|
Direct |
42,300
+50.0%
|
$211,500
$5.91 P/Share
|
|
Oct 02
2023
|
Franklyn G Prendergast Director |
BUY
Grant, award, or other acquisition
|
Direct |
60,840
+50.0%
|
-
|
|
Oct 02
2023
|
Michael Rapp Director |
BUY
Grant, award, or other acquisition
|
Direct |
253,806
+19.16%
|
$1,269,030
$5.91 P/Share
|
|
Jan 15
2023
|
Philip Wagenheim |
BUY
Grant, award, or other acquisition
|
Direct |
8,750
+2.11%
|
$35,000
$4.0 P/Share
|
|
Jan 15
2023
|
Michael Rapp Director |
BUY
Grant, award, or other acquisition
|
Direct |
17,500
+2.1%
|
$70,000
$4.0 P/Share
|
|
Jan 15
2023
|
Michael Lefenfeld Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,875
+25.4%
|
$55,500
$4.0 P/Share
|
|
Jan 15
2023
|
John L Lamattina Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,125
+18.43%
|
$60,500
$4.0 P/Share
|
|
Sep 13
2021
|
Michael Rapp Director |
BUY
Open market or private purchase
|
Indirect |
25,962
+11.06%
|
$493,278
$19.96 P/Share
|
|
Sep 10
2021
|
Michael Rapp Director |
BUY
Open market or private purchase
|
Indirect |
15,500
+7.82%
|
$263,500
$17.85 P/Share
|
|
Sep 09
2021
|
Michael Rapp Director |
BUY
Open market or private purchase
|
Indirect |
30,450
+8.54%
|
$517,650
$17.95 P/Share
|
|
Aug 18
2021
|
Richard A Baron Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,343
+50.0%
|
$25,773
$11.38 P/Share
|
|
May 26
2021
|
Michael Rapp Director |
BUY
Open market or private purchase
|
Indirect |
2,300
+1.65%
|
$41,400
$18.94 P/Share
|
|
May 26
2021
|
Michael Lefenfeld Director |
BUY
Open market or private purchase
|
Direct |
1,335
+4.73%
|
$25,365
$19.03 P/Share
|
|
May 25
2021
|
Purnanand D Sarma President and CEO |
BUY
Open market or private purchase
|
Direct |
10,500
+50.0%
|
$189,000
$18.41 P/Share
|
|
May 25
2021
|
Michael Rapp Director |
BUY
Open market or private purchase
|
Indirect |
19,303
+12.55%
|
$347,454
$18.32 P/Share
|
|
May 25
2021
|
Michael Lefenfeld Director |
BUY
Open market or private purchase
|
Direct |
2,715
+9.61%
|
$48,870
$18.44 P/Share
|
|
May 24
2021
|
John L Lamattina Director |
BUY
Open market or private purchase
|
Direct |
5,440
+4.84%
|
$97,920
$18.51 P/Share
|
|
May 24
2021
|
Philip Wagenheim |
BUY
Open market or private purchase
|
Direct |
13,500
+3.29%
|
$243,000
$18.35 P/Share
|
|
May 24
2021
|
Michael Rapp Director |
BUY
Open market or private purchase
|
Indirect |
31,895
+21.68%
|
$574,110
$18.38 P/Share
|
|
May 24
2021
|
Michael Lefenfeld Director |
BUY
Open market or private purchase
|
Direct |
600
+2.56%
|
$10,200
$17.8 P/Share
|
|
Oct 06
2020
|
John L Lamattina Director |
BUY
Conversion of derivative security
|
Direct |
46,388
+50.0%
|
-
|
|
Oct 06
2020
|
Michael Lefenfeld Director |
BUY
Conversion of derivative security
|
Direct |
22,222
+50.0%
|
-
|
|
Oct 06
2020
|
I Wistar Morris Iii > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
38,464
+50.0%
|
-
|
|
Oct 06
2020
|
I Wistar Morris Iii > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
882,475
+50.0%
|
-
|
|
Oct 06
2020
|
Michael Rapp Director |
BUY
Open market or private purchase
|
Direct |
83,332
+11.54%
|
$999,984
$12.0 P/Share
|
|
Oct 06
2020
|
Michael Rapp Director |
BUY
Conversion of derivative security
|
Direct |
555,554
+50.0%
|
-
|
|
Oct 06
2020
|
Michael Widlitz Director |
BUY
Conversion of derivative security
|
Direct |
51,315
+50.0%
|
-
|